No Data
No Data
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Express News | Immunocore Announces Reimbursement Agreement in England for Kimmtrak▼ for the Treatment of Hla-a*02:01-Positive Adults With Unresectable or Metastatic Uveal Melanoma
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $74